Profusa Signs LOI to Acquire BioInsights' PanOmics Platform
Profusa announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights. The company believes this acquisition, adding to its core real-time biochemistry monitoring platform, will help to position Profusa at the intersection of biosensing, diagnostics, and precision medicine, establishing a foundation for scalable multi-product diagnostics and monitoring franchise. Under the terms of the Letter of Intent: Profusa would acquire exclusive rights to the PanOmics platform and related know-how; Total consideration of approximately $30 million, to be paid in equity securities; BioInsights to provide access to a specified number of samples for validation; BioInsights to receive a 3% royalty on net revenue; Profusa intends to pursue additional financing to support development and scale; BioInsights will have the right to nominate one independent Board member for consideration by stockholders to replace an outgoing Board member; The proposed transaction remains subject to completion of due diligence, shareholder approval, and customary closing conditions.
